Cargando…
Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis
BACKGROUND: Androgen deprivation therapy (ADT) is the effective treating prostate cancer but is often accompanied by cancer treatment-induced bone loss (CTIBL), which impairs the patient’s quality of life. In patients with nonmetastatic castration-sensitive prostate cancer (M0CSPC) who already have...
Autores principales: | Watanabe, Daisuke, Kimura, Takahiro, Watanabe, Ken, Takano, Hiromitsu, Uehara, Yuko, Minowa, Tadaaki, Yamashita, Akemi, Yoshikawa, Seiichiro, Mizushima, Akio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052675/ https://www.ncbi.nlm.nih.gov/pubmed/33863312 http://dx.doi.org/10.1186/s12885-021-08177-w |
Ejemplares similares
-
Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma
por: Watanabe, Daisuke, et al.
Publicado: (2019) -
Penile strangulation intentionally using a rubber band to prevent the development of penile cancer
por: Yoshida, Takahiro, et al.
Publicado: (2019) -
Treatment of postmenopausal osteoporosis, patient perspectives – focus on once yearly zoledronic acid
por: Carmona, Raj, et al.
Publicado: (2009) -
Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014) -
Safety and effectiveness of once-yearly zoledronic acid in Japanese osteoporosis patients: three-year post-marketing surveillance
por: Takada, Junichi, et al.
Publicado: (2023)